CagriSema vs tirzepatide: what the head-to-head showed

Two mechanisms, two different bets

Tirzepatide hits two receptors: GLP-1 and GIP. The GLP-1 component slows digestion and quiets appetite signals in the brain. The GIP component amplifies insulin response and has direct effects on adipose tissue that reduce fat storage. Adding GIP to GLP-1 worked better than anyone expected. SURMOUNT-1 showed tirzepatide at 15mg producing 20.9% weight loss at 72 weeks, compared to roughly 15% for semaglutide in comparable trials. That gap is why tirzepatide became the fastest-selling drug in pharmaceutical history.

Novo Nordisk took a different route. Instead of adding GIP, it combined semaglutide 2.4mg with cagrilintide, a long-acting amylin analog. Amylin is a pancreatic hormone that signals satiety through the brainstem, specifically the area postrema and nucleus tractus solitarius. That pathway is separate from the hypothalamic appetite circuits GLP-1 targets. Two satiety systems working together, Novo Nordisk argued, would add up to something tirzepatide could not match.

REDEFINE 4 ran the direct test.

CagriSema vs tirzepatide: what REDEFINE 4 found

REDEFINE 4 enrolled 809 adults with obesity and at least one weight-related comorbidity. Both arms ran for 84 weeks at maximum approved doses. The primary endpoint was non-inferiority: could CagriSema perform within a pre-specified margin of tirzepatide?

It could not.

CagriSema produced 23% mean weight loss at 84 weeks. Tirzepatide produced 25.5%. The 2.5-point gap crossed the non-inferiority threshold, meaning the trial concluded CagriSema could not be shown to be as good as tirzepatide. Not close enough was the finding, not a near miss.

That result was a setback for Novo Nordisk. The company had positioned CagriSema as a drug capable of taking market share from tirzepatide. A loss in the direct head-to-head made that case harder to build with prescribers and payers. 23% weight loss is genuinely good. Losing by 2.5 points in the same trial, against the drug you are trying to displace, is a problem for commercial positioning.

Why GIP beat amylin in this comparison

GIP agonism is powerful in ways that took researchers some time to understand. It amplifies insulin secretion. It also has direct effects on fat tissue: GIP receptors in adipocytes affect how fat is stored and released. Combining GIP with GLP-1 produces results consistently stronger than either alone, and those results have held up from Phase 2 through the full SURMOUNT program.

Amylin works too. REDEFINE 1 proved that. But the two additive mechanisms are not equal. When tested against each other in 809 people over 84 weeks, the GLP-1 plus GIP combination produced more weight loss than GLP-1 plus amylin.

What REDEFINE 4 did not settle is whether the gap holds across all relevant outcomes. Weight loss at 84 weeks is one data point. Cardiovascular risk reduction, liver fat, muscle preservation during weight loss, and T2D glycemic outcomes are distinct measures. GIP and amylin act on different downstream systems. The picture on those dimensions is not settled by a single weight loss comparison. Future data may close some of the gap. It may not.

CagriSema's strongest case: what it does to semaglutide

REDEFINE 4 was not the first REDEFINE trial. REDEFINE 1 enrolled 3,417 adults without type 2 diabetes and ran three arms: CagriSema, semaglutide alone, and cagrilintide alone. The numbers make a strong case for the combination.

CagriSema: 22.7% mean weight loss at 68 weeks. Semaglutide alone: 16.1%. Cagrilintide alone: 11.8%. About 60% of CagriSema participants lost at least 20% of their body weight. About 23% lost 30% or more. Those are tirzepatide-level results in a Novo Nordisk trial.

Stated plainly: if you are on semaglutide and the results are not where you want them, CagriSema adds roughly 6.6 percentage points of additional weight loss. That is clinically meaningful. Many people on Wegovy plateau at 12 to 15%. An added 6 or 7 points would be consequential for them.

The complication is that tirzepatide also outperforms semaglutide, produces results similar to or better than CagriSema, and is already available with a prescription. For someone responding poorly to semaglutide, switching to tirzepatide is an option today. CagriSema is not.

New data from ADA 2026: the REIMAGINE trials

The American Diabetes Association 2026 Scientific Sessions, held in June, included new CagriSema data from the REIMAGINE program. Where REDEFINE enrolled adults with obesity primarily without type 2 diabetes, REIMAGINE studied CagriSema in T2D patients across the full glycemic spectrum.

The REIMAGINE results showed CagriSema reducing HbA1c across multiple T2D subtypes, paired with meaningful weight loss. For clinicians managing type 2 diabetes, that changes the frame. The obesity weight loss headline matters. Glycemic control, cardiovascular risk reduction, and liver outcomes matter too, often more for their specific patients.

Tirzepatide's T2D case is already well established through the SURPASS program and its approval for type 2 diabetes. REIMAGINE gives CagriSema a competing argument in that population. The full published dataset from REIMAGINE is not yet out as of late June 2026. Conference results are preliminary. But they establish that the CagriSema story in T2D is not closed by the REDEFINE 4 obesity headline.

One is approved; one is not

Tirzepatide is in pharmacies. CagriSema is not. Novo Nordisk filed for FDA approval in December 2025 based on REDEFINE 1 and REDEFINE 2. The standard FDA review timeline is 10 to 12 months, which puts a decision in late 2026 under the most optimistic scenario. That timeline can extend.

Cost is also unsettled for CagriSema. Tirzepatide's brand pricing is established, and compounded tirzepatide is available through licensed 503A pharmacies at meaningfully lower prices in most states. CagriSema will not have a compounded version at launch. What Novo Nordisk charges, and how insurance covers it, will shape real-world uptake more than the REDEFINE 4 weight loss numbers once the drug eventually reaches pharmacies.

Where each drug fits right now

For most people who need treatment today, tirzepatide is the stronger choice. The REDEFINE 4 head-to-head confirmed it on the primary outcome. It is approved and available. Compounded versions reduce cost access significantly. The data from SURMOUNT-1 through REDEFINE 4 consistently puts tirzepatide ahead on weight loss numbers. If you are deciding what to start, tirzepatide is where the evidence points.

CagriSema will matter when it launches. Not because it beats tirzepatide on average, but because metabolic drug response varies across patients. Some people respond poorly to GIP agonism. The amylin pathway is genuinely different. Prescribers will have a new option for patients who try tirzepatide and plateau early or do not tolerate it well.

The bigger picture: both drugs are better than semaglutide alone. For someone on Wegovy for two years wondering what comes next, either CagriSema or tirzepatide represents a meaningful step forward. The jump from semaglutide to the next generation is roughly 6 to 10 percentage points of additional weight loss. That is the generation shift that matters most for existing GLP-1 users.

One generation further out, retatrutide posted 28.3% weight loss in TRIUMPH-1 with 2,339 adults. That is ahead of both CagriSema and tirzepatide at comparable durations. The full TRIUMPH-1 data is covered separately, but it frames where the drug class is heading.

For the current comparison: tirzepatide leads CagriSema by 2.5 points in the only direct trial that exists. Until the REIMAGINE published data changes that picture, or until CagriSema earns FDA approval and launches at a price that works, tirzepatide is the call.